HNN3.0

Project cooperationUpdated on 24 January 2026

Bioprocessing and Quality-by-Design Platforms for Cell-, Gene- and EV-Based ATMPs

Research Manager at Institute for Bioengineering and Biosciences

Lisboa, Portugal

About

What we aim to do

Strengthen cell-, gene- and extracellular-vesicle-based ATMP development and deployment by integrating advanced biological platforms with robust bioprocessing, quality-by-design and frameworks.

What we can contribute

  1. Upstream and downstream bioprocess development for stem and immune cells (HSPC, MSC, NK) and extracellular vesicles

  2. Quality-by-design approaches, including CQAs, CPPs, quality control strategies and functional potency assays

  3. DNA- and RNA-based downstream analytics supporting identity, purity, stability and comparability assessments

  4. Assessment of robustness, cryopreservation and transport informing ATMP manufacturing and logistics

  5. Precision gene and epigenetic editing combined with patient-derived iPSC and organoid models to analyse biological variability, stability and durability

Partners we are looking for

ATMP developers, GMP manufacturers and CDMOs, clinical translation partners, regulatory science groups and ATMP-focused research infrastructures.

Topic

  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)

Type

  • Partner seeks Consortium/Coordinator

Organisation

Institute for Bioengineering and Biosciences

R&D Institution

Lisboa, Portugal

Similar opportunities